European CHMP recommends approval of biosimilar of teriparatide (Qutavina) ) 20 micrograms/80 microlitres solution for injection

Teriparatide, the active aminoterminal fragment of human parathyroid hormone, acts via the receptor for parathyroid hormone and has an anabolic effect on bone. Teriparatide is licensed for treatment of osteoporosis in postmenopausal women and men at increased risk of fracture.

European Medicines Agency